Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Vasopressin is antidiuretic hormone. It is naturally secreted by the pituitary gland, which acts on the kidneys and blood vessels. Vasopressin is used in the treatment of diabetes insipidus and certain conditions of the stomach after surgery or during abdominal x-rays. It is administered into a muscle or under the skin, or into a vein.
The global vasopressin market is estimated to be valued at US$ 1,112.6 million in 2021 and is expected to exhibit a CAGR of 14.7% over the forecast period (2021-2028).
Figure 1. Global Vasopressin Market Share (%) in Terms of Value, By Region, 2021
Increasing prevalence of autonomic dysreflexia (AD) is expected to drive growth of the global vasopressin market.
According to the National Center for Biotechnology Information (NCBI) 2017, the prevalence of AD in patients with spinal cord injury (SCI) has been reported to range from 20 to 70%, and it is known to occur in over 90% of patients with cervical or upper thoracic SCI.
Vasopressin Market Report Coverage
||Market Size in 2021:
||US$ 1,112.6 Mn
|Historical Data for:
||2017 to 2020
||2021 to 2028
|Forecast Period 2021 to 2028 CAGR:
||2028 Value Projection:
||US$ 2,912.0 Mn
- North America: U.S. and Canada
- Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
- Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
- Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
- Middle East: GCC Countries, Israel, and Rest of Middle East
- Africa: South Africa, North Africa, and Central Africa
- By Type: Intravenous Injection, Intramuscular Injection, Subcutaneous Injection
- By Application: Anti-Diuretic Hormone Deficiency, Gastrointestinal Bleeding, Vasodilatory Shock, Ventricular Tachycardia & Fibrillation
- By End User: Hospital, Clinics, Others
Par Pharmaceutical, Pfizer Inc., Novartis AG, Ferring Pharmaceuticals, Fresenius Kabi Canada, Astellas Pharma, Shanghai Soho-Yiming Pharmaceuticals, Endo International, Hybio Pharmaceutical, Hainan Zhonghe Pharmaceutical, and Cumberland Pharmaceuticals
- Increasing prevalence of autonomic dysreflexia (AD)
- Approval of Vasopressin Drug
|Restraints & Challenges:
- Potential side effects of Vasopressin Drugs
Figure 2. Global Vasopressin Market Share (%), by Type, 2021
The increasing regulatory approvals for vasopressin drug is expected to drive the market growth over the forecast period. For instance, in June 2021, Eagle Pharmaceuticals, Inc., announced that the U.S. Food and Drug and Administration priority review for the company’s abbreviated new drug application for its vasopressin.
The Eagle Pharmaceuticals, Inc., company’s response to the Complete Response Letter (CRL) was submitted on June 15, 2021. The U.S. FDA assigned a Generic Drug User Fee Amendments/Act GDUFA date of December 15, 2021
Global Vasopressin Market– Impact of Coronavirus (COVID-19) Pandemic-
The recent increasing cases of people suffering from Novel corona virus is expected to sudden increase of cardiac syndrome risk amongst people . This is leading the pharma sector to focus on research and development on advanced vasopressin drugs for treatment purposes. This is expected to boost the growth of the global market in the near future.
Global Vasopressin Market- Restraint
The major factor that is expected to hinder growth of the global vasopressin market include complication resulting from the use vasopressin such as asthma, epilepsy, heart disease, and heart failure.
Major players operating in the global vasopressin market include Par Pharmaceutical, Pfizer Inc., Novartis AG, Ferring Pharmaceuticals, Fresenius Kabi Canada, Astellas Pharma, Shanghai Soho-Yiming Pharmaceuticals, Endo International, Hybio Pharmaceutical, Hainan Zhonghe Pharmaceutical, and Cumberland Pharmaceuticals.